ALSO NOTED: Genzyme can't make Myozyme at Boston plant; Ranbaxy, Orchid forge drug-and-API deal;

> FDA won't let Genzyme make its uber-expensive Pompe disease treatment Myozyme at its Boston plant because of a small difference between the batches of Myozyme Genzyme makes now and the new larger batches it was to produce; the regulatory crackdown will leave the drug in short supply in the U.S. and depress Genzyme's 2008 earnings. Report [1]

> Ranbaxy inked a deal with Orchid Chemicals & Pharmaceuticals for multiple finished dosages and active pharmaceutical ingredients. Release [2]

> A Nevada judge ordered Wyeth to post a $58 million bond and pay $1.6 million in attorney's fees for acting in 'bad faith' during settlement talks in the case of three women who sued over the Prempro hormone replacement therapy. Report [3]

> Two drug companies outsourced chunks of their IT systems: Nycomed hired British Telecommunications and Hewlett-Packard to provide it with IT infrastructure, and Janssen Pharmaceuticals tapped Porthus to manage all its electronic customs programming in Belgium. Report [4]

> Celgene got regulatory approval to sell its thalidomide drug in the EU, for use in combination with two other meds for treating multiple myeloma. Report [5]

> Roche's Japanese unit Chugai upped its full-year profit expectations to ¥29 billion from ¥17 billion after government drug-price cuts came in smaller than expected. Report [6]

> Mylan got the FDA nod for its copycat version of AstraZeneca's blood pressure pill Plendil. Report [7]

> Four of San Diego's biggest research institutions are teaming up to form the San Diego Consortium for Regenerative Medicine, a group aimed at advancing stem cell work. And they're planning a $115 million research "collaboratory" that would open in 2010. Report [8]

> Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. Report [9]

> The bill on sequencing a genome has fallen from a few billion dollars to about $60,000 in just five years. And now two companies want to use nanotech to knock that price down to just $100. Report [10]

> University of Cincinnati researcher Melissa DelBello is getting some added scrutiny for failing to disclose large sums of money she received from AstraZeneca a year after completing a study of Seroquel for bipolar disease. Report [11]

And Finally... "Chemo brain" symptoms may not be byproducts of fatigue and depression associated with cancer treatment, but side effects of a common chemo drug, 5-fluorouracil, a new study found. Report [12]